PEPG
PepGen Inc.
$1.66
-$0.01(-0.90%)
35
Overall
60
Value
10
Tech
--
Quality
Market Cap
$149.24M
Volume
769.75K
52W Range
$0.88 - $7.80
Target Price
$10.29
Company Overview
| Mkt Cap | $149.24M | Price | $1.66 |
| Volume | 769.75K | Change | -0.90% |
| P/E Ratio | -1.7 | Open | $1.73 |
| Revenue | -- | Prev Close | $1.67 |
| Net Income | $-90.0M | 52W Range | $0.88 - $7.80 |
| Div Yield | N/A | Target | $10.29 |
| Overall | 35 | Value | 60 |
| Quality | -- | Technical | 10 |
No chart data available
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Latest News
Wall Street Analysts Are Bullish on Top Healthcare Picks
Brian Anderson•4 days ago
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), PepGen Inc. (PEPG) and Omeros (OMER)
Brian Anderson•7 days ago
PepGen Reports Early Phase 2 FREEDOM2-DM1 Topline Data
TipRanks Auto-Generated Newsdesk•9 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PEPG | $1.66 | -0.9% | 769.75K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |